Abstract
Background Bi-allelic pathogenic variants in GBA1 are the cause of Gaucher disease (GD1), a lysosomal storage disorder resulting from deficient glucocerebrosidase. Heterozygous GBA1 variants are also a common genetic risk factor for Parkinson’s disease (PD). GD manifests with considerable clinical heterogeneity and is also associated with an increased risk of PD.
Objective To investigate the contribution of PD risk variants to risk of PD in patients with GD1.
Methods We studied 225 patients with GD1, including 199 without PD and 26 with PD. All cases were genotyped and the genetic data was imputed using common pipelines.
Results On average, patients with GD1 with PD have a significantly higher PD genetic risk score than those without PD (P=0.021).
Conclusions Our results indicate that variants included in the PD genetic risk score were more frequent in patients with GD1 who developed PD, suggesting that common risk variants may affect underlying biological pathways.
Supplemental data here
Competing Interest Statement
Financial Disclosures M.A.N. and D.V. are consultants employed by Data Tecnica International, whose participation in this is part of a consulting agreement between the US National Institutes of Health and said company.
Funding Statement
This work was supported in part by the Intramural Research Program of the National Human Genome Research Institute (NHGRI), the Center for Alzheimer`s and Related Dementias, within the Intramural Research Program of the National Institute on Aging and the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services, and the National Institutes of Health and Cure Parkinson`s (UK).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Each contributing study abided by the ethics guidelines set out by their institutional review boards, and all participants gave informed consent for inclusion in both their initial cohorts and subsequent studies. The research of these cohorts was deemed not human subjects research by the NIH Office of IRB Operations which stated that no IRB approval is required. Data used in the preparation of this article were obtained from Global Parkinson`s Genetics Program (GP2, http://gp2.org/).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Relevant conflicts of interest/financial disclosures: M.A.N. and D.V. are consultants employed by Data Tecnica International, whose participation in this is part of a consulting agreement between the US National Institutes of Health and said company.
Funding agencies: This work was supported in part by the Intramural Research Program of the National Human Genome Research Institute (NHGRI), the Center for Alzheimer’s and Related Dementias, within the Intramural Research Program of the National Institute on Aging and the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services, and the National Institutes of Health and Cure Parkinson’s (UK). Data used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research (https://gp2.org).
Data Availability
All data produced in the present work are contained in the manuscript.
